In December 2012, Christopher Cox, cochair of the corporate group at Cadwalader, Wickersham & Taft, was retained by Irish drugmaker Élan Corporation PLC to advise on the sale of its stake in Tysabri, a multiple sclerosis drug. It should have been a quick and relatively straightforward engagement: Cox, who is based in New York, had represented the company on eight transactions of more than $1 billion in the past seven years alone. But it would be a full 12 months before Cox finally finished the transaction, and not before dealing with a hostile takeover bid and the eventual sale of Élan itself. “This was by a stretch the longest transaction that I’ve ever worked on,” Cox says. “It was a long, difficult process.”
To view this content, please continue to Lexis Advance®.
Not a Lexis Advance® Subscriber? Subscribe Now
LexisNexis® is now the exclusive third party online distributor of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® customers will be able to access and use ALM's content by subscribing to the LexisNexis® services via Lexis Advance®. This includes content from the National Law Journal®, The American Lawyer®, Law Technology News®, The New York Law Journal® and Corporate Counsel®, as well as ALM's other newspapers, directories, legal treatises, published and unpublished court opinions, and other sources of legal information.
ALM's content plays a significant role in your work and research, and now through this alliance LexisNexis® will bring you access to an even more comprehensive collection of legal content.
For questions call 1-877-256-2472 or contact us at firstname.lastname@example.org